Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $57.23 and last traded at $57.23, with a volume of 859 shares changing hands. The stock had previously closed at $63.79.
Wall Street Analyst Weigh In
Separately, William Blair upgraded Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research note on Friday, March 7th.
Check Out Our Latest Stock Analysis on Zealand Pharma A/S
Zealand Pharma A/S Trading Down 4.6%
The company has a debt-to-equity ratio of 0.03, a current ratio of 25.10 and a quick ratio of 25.07. The business's fifty day simple moving average is $66.40 and its 200 day simple moving average is $84.34. The stock has a market cap of $4.06 billion, a price-to-earnings ratio of -22.98 and a beta of 0.74.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.77) by $0.10. The business had revenue of $1.14 million during the quarter, compared to the consensus estimate of $248.61 million. Zealand Pharma A/S had a negative net margin of 2,127.09% and a negative return on equity of 13.40%. On average, research analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.
About Zealand Pharma A/S
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Further Reading
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
